Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer
|
摘要
Cisplatin, a platinum-based chemotherapeutic drug, has been used for over 30 years in a wide variety of cancers with varying degrees of success. In particular, cisplatin has been used to treat late stage non-small cell lung cancer(NSCLC) as the standard of care. However, therapeutic outcomes vary from patient to patient. Considerable efforts have been invested to identify biomarkers that can be used to predict cisplatin sensitivity in NSCLC. Here we reviewed current evidence for cisplatin sensitivity biomarkers in NSCLC. We focused on several key pathways, including nucleotide excision repair, drug transport and metabolism. Both expression and germline DNA variation were evaluated in these key pathways. Current evidence suggests that cisplatin-based treatment could be improved by the use of these biomarkers.
Cisplatin, a platinum-based chemotherapeutic drug, has been used for over 30 years in a wide variety of cancers with varying degrees of success. In particular, cisplatin has been used to treat late stage non-small cell lung cancer(NSCLC) as the standard of care. However, therapeutic outcomes vary from patient to patient. Considerable efforts have been invested to identify biomarkers that can be used to predict cisplatin sensitivity in NSCLC. Here we reviewed current evidence for cisplatin sensitivity biomarkers in NSCLC. We focused on several key pathways, including nucleotide excision repair, drug transport and metabolism. Both expression and germline DNA variation were evaluated in these key pathways. Current evidence suggests that cisplatin-based treatment could be improved by the use of these biomarkers.
Cisplatin, a platinum-based chemotherapeutic drug, has been used for over 30 years in a wide variety of cancers with varying degrees of success. In particular, cisplatin has been used to treat late stage non-small cell lung cancer(NSCLC) as the standard of care. However, therapeutic outcomes vary from patient to patient. Considerable efforts have been invested to identify biomarkers that can be used to predict cisplatin sensitivity in NSCLC. Here we reviewed current evidence for cisplatin sensitivity biomarkers in NSCLC. We focused on several key pathways, including nucleotide excision repair, drug transport and metabolism. Both expression and germline DNA variation were evaluated in these key pathways. Current evidence suggests that cisplatin-based treatment could be improved by the use of these biomarkers.
引文
[1]WHO cancer factsheet.
[2]American Cancer Society.Cancer facts and figures2014.Atlanta:American Cancer Society;2014.
[3]Yin JY,Huang Q,Zhao YC,Zhou HH,Liu ZQ.Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer(NSCLC)patients.PLo S One2012;7:e38150.
[4]National Cancer Institute.Non-small cell lung cancer treatment.;2014[accessed25.05.14].
[5]Siegel R,Ma J,Zou Z,Jemal A.Cancer statistics,2014.CA Cancer J Clin 2014;64:9–29.
[6]Kuo MT,Chen HH,Song IS,Savaraj N,Ishikawa T.The roles of copper transporters in cisplatin resistance.Cancer Metastasis Rev 2007;26:71–83.
[7]van der Straaten T,Mullenders L,Guchelaar HJ.Pharmacogenetics of cancer and DNA repair enzymes.In:Vengrova S,editor.DNA repair and human health[internet].Richardson:Intech;2011.p.597–612.
[8]Rabik CA,Dolan ME.Molecular mechanisms of resistance and toxicity associated with platinating agents.Cancer Treat Rev2007;33:9–23.
[9]Huang JC,Zamble DB,Reardon JT,Lippard SJ,Sancar A.HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.Proc Natl Acad Sci U S A 1994;91:10394–8.
[10]Fichtinger-Schepman AM,van der Veer JL,den Hartog JH,Lohman PH,Reedijk J.Adducts of the antitumor drug cisdiamminedichloroplatinum(ii)with DNA–formation,identification,and quantitation.Biochemistry 1985;24:707–13.
[11]Zamble DB,Mu D,Reardon JT,Sancar A,Lippard SJ.Repair of cisplatin-DNA adducts by the mammalian excision nuclease.Biochemistry 1996;35:10004–13.
[12]Kartalou M,Essigmann JM.Mechanisms of resistance to cisplatin.Mutat Res Fundam Mol Mech Mutagen2001;478:23–43.
[13]Rosell R,Lord RV,Taron M,Reguart N.DNA repair and cisplatin resistance in non-small-cell lung cancer.Lung Cancer2002;38:217–27.
[14]Furuta T,Ueda T,Aune G,Sarasin A,Kraemer KH,Pommier Y.Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.Cancer Res2002;62:4899–902.
[15]Rosell R,Taron M,Barnadas A,Scagliotti G,Sarries C,Roig B.Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.Cancer Control2003;10:297–305.
[16]De Silva IU,Mc Hugh PJ,Clingen PH,Hartley JA.Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.Nucleic Acids Res 2002;30:3848–56.
[17]Dabholkar M,Vionnet J,Bostickbruton F,Yu JJ,Reed E.Messenger-RNA levels of XPAC and ERCC1 in ovarian-cancer tissue correlate with response to platinum-based chemotherapy.J Clin Invest 1994;94:703–8.
[18]Takenaka T,Yoshino I,Kouso H,Ohba T,Yohena T,Osoegawa A,et al.Combined evaluation of Rad51 and ERCC1expressions for sensitivity to platinum agents in non-small cell lung cancer.Int J Cancer 2007;121:895–900.
[19]Wang L,Wei J,Qian X,Yin H,Zhao Y,Yu L,et al.ERCC1and BRCA1 m RNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.BMC Cancer 2008;8:97.
[20]Lord RV,Brabender J,Gandara D,Alberola V,Camps C,Domine M,et al.Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.Clin Cancer Res 2002;8:2286–91.
[21]Cobo M,Isla D,Massuti B,Montes A,Sanchez JM,Provencio M,et al.Customizing cisplatin based on quantitative excision repair cross-complementing 1 m RNA expression:a phase III trial in non-small-cell lung cancer.J Clin Oncol 2007;25:2747–54.
[22]Olaussen KA,Dunant A,Fouret P,Brambilla E,Andre F,Haddad V,et al.DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.N Engl J Med 2006;355:983–91.
[23]Fan W,Zhang HL,Wu XM.Enhancement effect of nucleotide excision repair gene xeroderma pigmentosum group A antisense RNA on sensitivity of human lung adenocarcinoma cell line A549 to cisplatin.Chin J Cancer 2005;24:403–7.
[24]Zhang Q,Wu JX,Wei YP,Hao JQ,Huang SY,Dong L.Effect of XPA expression on the chemotherapy sensitivity of A549/DDP cells.Chin J Cell Mol Immunol 2012;28:1182–4.
[25]Liu Y,Bernauer AM,Yingling CM,Belinsky SA.HIF1 alpha regulated expression of XPA contributes to cisplatin resistance in lung cancer.Carcinogenesis 2012;33:1187–92.
[26]Chen HH,Yan JJ,Chen WC,Kuo MT,Lai YH,Lai WW,et al.Predictive and prognostic value of human copper transporter 1(h Ctr1)in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.Lung Cancer 2012;75:228–34.
[27]Song IS,Savaraj N,Siddik ZH,Liu PM,Wei YJ,Wu CJ,et al.Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.Mol Cancer Ther 2004;3:1543–9.
[28]Lin XJ,Okuda T,Holzer A,Howell SB.The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae.Mol Pharmacol 2002;62:1154–9.
[29]Ishida S,Lee J,Thiele DJ,Herskowitz I.Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals.Proc Natl Acad of Sci U S A2002;99:14298–302.
[30]Li ZH,Qiu MZ,Zeng ZL,Luo HY,Wu WJ,Wang F,et al.Copper-transporting P-type adenosine triphosphatase(ATP7A)is associated with platinum-resistance in non-small cell lung cancer(NSCLC).J Transl Med 2012;10:21.
[31]Song L,Li Y,Li W,Wu S,Li Z.Mi R-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper transporting P-type adenosine triphosphatase A(ATP7A).J Cell Biochem 2014;115:1234–42.
[32]Nakayama K,Kanzaki A,Terada K,Mutoh M,Ogawa K,Sugiyama T,et al.Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.Clin Cancer Res 2004;10:2804–11.
[33]Konkimalla VB,Kaina B,Efferth T.Role of transporter genes in cisplatin resistance.In Vivo 2008;22:279–83.
[34]Inoue Y,Matsumoto H,Yamada S,Kawai K,Suemizu H,Gika M,et al.ATP7B expression is associated with in vitro sensitivity to cisplatin in non-small cell lung cancer.Oncol Lett2010;1:279–82.
[35]Nakagawa T,Inoue Y,Kodama H,Yamazaki H,Kawai K,Suemizu H,et al.Expression of copper-transporting P-type adenosine triphosphatase(ATP7B)correlates with cisplatin resistance in human non-small cell lung cancer xenografts.Oncol Rep 2008;20:265–70.
[36]Nakagawa K,Yokota J,Wada M,Sasaki Y,Fujiwara Y,Sakai M,et al.Levels of glutathione S transferase pi m RNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin.Jpn J Cancer Res 1988;79:301–4.
[37]Arai T,Yasuda Y,Takaya T,Yoshimi N,Ito H,Fujiwara H.Correlation between the immunohistochemical and m RNA expression of glutathione S-transferase-pi and cisplatin plus etoposide chemotherapy response in patients with untreated primary non-small cell lung cancer.Int J Oncol 1997;11:127–31.
[38]Arai T,Yasuda Y,Takaya T,Hayakawa K,Toshima S,Shibuya C,et al.Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small-cell lung cancer.Cancer Detect Prev 2000;24:252–7.
[39]Hida T,Ariyoshi Y,Kuwabara M,Sugiura T,Takahashi T,Hosoda K,et al.Glutathione S-transferase pi levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity.Jpn J Clin Oncol 1993;23:14–9.
[40]Hirano T,Kato H,Maeda M,Gong YB,Shou YN,Nakamura M,et al.Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker.Int J Cancer 2005;117:460–8.
[41]Allen TC,Granville LA,Cagle PT,Haque A,Zander DS,Barrios R.Expression of glutathione S-transferase pi and glutathione synthase correlates with survival in early stage nonsmall cell carcinomas of the lung.Hum Pathol 2007;38:220–7.
[42]Rosell R,Scagliotti G,Danenberg KD,Lord RV,Bepler G,Novello S,et al.Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.Oncogene 2003;22:3548–53.
[43]Townsend AJ,Tu CP,Cowan KH.Expression of human mu or alpha class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells:effect on cellular sensitivity to cytotoxic agents.Mol Pharmacol 1992;41:230–6.
[44]Waxman DJ,Sundseth SS,Srivastava PK,Lapenson DP.Genespecific oligonucleotide probes for alpha,mu,pi,and microsomal rat glutathione S-transferases:analysis of liver transferase expression and its modulation by hepatic enzyme inducers and platinum anticancer drugs.Cancer Res 1992;52:5797–802.
[45]Wang CH,Wu HT,Cheng HM,Yen TJ,Lu IH,Chang HC,et al.Inhibition of glutathione S-transferase M1 by new gabosine analogues is essential for overcoming cisplatin resistance in lung cancer cells.J Med Chem 2011;54:8574–81.
[46]Wachters FM,Wong LS,Timens W,Kampinga HH,Groen HJ.ERCC1,h Rad51,and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.Lung Cancer 2005;50:211–9.
[47]Booton R,Ward T,Ashcroft L,Morris J,Heighway J,Thatcher N.ERCC1 m RNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.J Thorac Oncol2007;2:902–6.
[48]Glaysher S,Yiannakis D,Gabriel FG,Johnson P,Polak ME,Knight LA,et al.Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer(NSCLC).BMC Cancer 2009;9:1–17.
[49]Friboulet L,Olaussen KA,Pignon JP,Shepard FA,Tsao MS,Graziano S,et al.ERCC1 isoform expression and DNA repair in non-small cell lung cancer.N Engl J Med 2013;368:1101–10.
[50]Schneider JG,Farhadfar N,Sivapiragasam A,Geller M,Islam S,Selbs E.Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.Oncologist 2014;19:459–65.
[51]Stewart DJ.Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.Crit Rev Oncol Hematol 2010;75:173–234.
[52]Wei SZ,Zhan P,Shi MQ,Shi Y,Qian Q,Yu LK,et al.Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinumbased chemotherapy:a systematic review and meta-analysis.Med Oncol 2011;28:315–21.
[53]Wei HB,Hu J,Shang LH,Zhang YY,Lu FF,Wei M,et al.A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced nonsmall cell lung cancer.Chin Med J(Engl)2012;125:2902–7.
[54]Yu D,Shi J,Sun T,Du X,Liu L,Zhang X,et al.Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.Tumor Biol 2012;33:877–84.
[55]Qin Q,Zhang C,Yang X,Zhu H,Yang B,Cai J,et al.Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients:a meta-analysis of 24 studies.PLo S One 2013;8:e79864.
[56]Xu X,Duan L,Zhou B,Ma R,Zhou H,Liu Z.Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.Clin Exp Pharmacol Physiol 2012;39:786–92.
[57]Wu X,Lu C,Ye Y,Chang J,Yang H,Lin J,et al.Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy.Pharmacogenet Genomics 2008;18:955–65.
[58]Sun N,Sun X,Chen B,Cheng H,Feng J,Cheng L,et al.MRP2and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.Cancer Chemother Pharmacol 2010;65:437–46.
[59]Zhou F,Yu Z,Jiang T,Lv H,Yao R,Liang J.Genetic polymorphisms of GSTP1 and XRCC1:prediction of clinical outcome of platinum-based chemotherapy in advanced nonsmall cell lung cancer(NSCLC)patients.Swiss Med Wkly2011;141:w13275.
[60]Booton R,Ward T,Heighway J,Ashcroft L,Morris J,Thatcher N.Glutathione S-transferase P1 isoenzyme polymorphisms,platinum-based chemotherapy,and non-small cell lung cancer.J Thorac Oncol 2006;1:679–83.
[61]Lu C,Spitz MR,Zhao H,Dong Q,Truong M,Chang JY,et al.Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma.Cancer 2006;106:441–7.
[62]Yang Y,Xian L.The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer(NSCLC)patients:a meta-analysis.Tumor Biol2014;35:6791–9.
[63]Moyer AM,Sun Z,Batzler AJ,Li L,Schaid DJ,Yang P,et al.Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy.Cancer Epidemiol Biomarkers Prev 2010;19:811–21.
[64]Wu XM,Fan W,Xu SW,Zhou YK.Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosum group A antisense RNA in human lung adenocarcinoma cells.Clin Cancer Res2003;9:5874–9.
[65]Rosenberg E,Taher MM,Kuemmerle NB,Farnsworth J,Valerie K.A truncated human xeroderma pigmentosum complementation group a protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin.Cancer Res 2001;61:764–70.
[66]Gately DP,Howell SB.Cellular accumulation of the anticancer agent cisplatin:a review.Br J Cancer 1993;67:1171–6.
[67]Kim ES,Lee JJ,He G,Chow CW,Fujimoto J,Kalhor N,et al.Tissue platinum concentration and tumor response in non-smallcell lung cancer.J Clin Oncol 2012;30:3345–52.
[68]Zhou B,Gitschier J.HCTR1:a human gene for copper uptake identified by complementation in yeast.Proc Natl Acad Sci U S A 1997;94:7481–6.
[69]Safaei R,Howell SB.Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.Crit Rev Oncol Hematol 2005;53:13–23.
[70]Holzer AK,Manorek GH,Howell SB.Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin,carboplatin,and oxaliplatin.Mol Pharmacol2006;70:1390–4.
[71]Zisowsky J,Koegel S,Leyers S,Devarakonda K,Kassack MU,Osmak M,et al.Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.Biochem Pharmacol2007;73:298–307.
[72]Larson CA,Blair BG,Safaei R,Howell SB.The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.Mol Pharmacol 2009;75:324–30.
[73]Larson CA,Adams PL,Jandial DD,Blair BG,Safaei R,Howell SB.The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin.Biochem Pharmacol 2010;80:448–54.
[74]Kalayda GV,Wagner CH,Jaehde U.Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.J Inorg Biochem 2012;116:1–10.
[75]Ishida S,Mc Cormick F,Smith-Mc Cune K,Hanahan D.Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.Cancer Cell 2010;17:574–83.
[76]Fu S,Naing A,Fu C,Kuo MT,Kurzrock R.Overcoming platinum resistance through the use of a copper-lowering agent.Mol Cancer Ther 2012;11:1221–5.
[77]Ivy KD,Kaplan JH.A re-evaluation of the role of h CTR1,the human high-affinity copper transporter,in platinum-drug entry into human cells.Mol Pharmacol 2013;83:1237–46.
[78]Hall MD,Okabe M,Shen DW,Liang XJ,Gottesman MM.The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.Annu Rev Pharmacol Toxicol2008;48:495–535.
[79]Wee NK,Weinstein DC,Fraser ST,Assinder SJ.The mammalian copper transporters CTR1 and CTR2 and their roles in development and disease.Int J Biochem Cell Biol 2013;45:960–3.
[80]Blair BG,Larson CA,Safaei R,Howell SB.Copper transporter2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.Clin Cancer Res 2009;15:4312–21.
[81]Huang CP,Fofana M,Chan J,Chang CJ,Howell SB.Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.Metallomics 2014;6:654–61.
[82]Ohrvik H,Thiele DJ.The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy.J Trace Elem Med Biol 2014.http://dx.doi.org/10.1016/j.jtemb.2014.03.006.
[83]Vulpe C,Levinson B,Whitney S,Packman S,Gitschier J.Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase.Nat Genet1993;3:7–13.
[84]Bull PC,Thomas GR,Rommens JM,Forbes JR,Cox DW.The Wilson disease gene is a putative copper transporting p-type ATPase similar to the Menkes gene.Nat Genet 1993;5:327–37.
[85]Samimi G,Varki NM,Wilczynski S,Safaei R,Alberts DS,Howell SB.Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.Clin Cancer Res2003;9:5853–9.
[86]Samimi G,Safaei R,Katano K,Holzer AK,Rochdi M,Tomioka M,et al.Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin,carboplatin,and oxaliplatin in ovarian cancer cells.Clin Cancer Res2004;10:4661–9.
[87]Komatsu M,Sumizawa T,Mutoh M,Chen ZS,Terada K,Furukawa T,et al.Copper-transporting P-type adenosine triphosphatase(ATP7B)is associated with cisplatin resistance.Cancer Res 2000;60:1312–6.
[88]Hildebrandt MA,Gu J,Wu X.Pharmacogenomics of platinumbased chemotherapy in NSCLC.Expert Opin Drug Metab Toxicol 2009;5:745–55.
[89]Fukushima-Uesaka H,Saito Y,Maekawa K,Kurose K,Sugiyama E,Katori N,et al.Genetic polymorphisms of copperand platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients.Drug Metab Pharmacokinet2009;24:565–74.
[90]Anttila S,Hirvonen A,Vainio H,Husgafvel-Pursiainen K,Hayes JD,Ketterer B.Immunohistochemical localization of glutathione S-transferases in human lung.Cancer Res1993;53:5643–8.
[91]Terrier P,Townsend AJ,Coindre JM,Triche TJ,Cowan KH.An immunohistochemical study of pi-class glutathione S-transferase expression in normal human tissue.Am J Pathol1990;137:845–53.
[92]Peklak-Scott C,Smitherman PK,Townsend AJ,Morrow CS.Role of glutathione S-transferase P1–1 in the cellular detoxification of cisplatin.Mol Cancer Ther 2008;7:3247–55.
[93]Tew KD.Glutathione-associated enzymes in anticancer drugresistance.Cancer Res 1994;54:4313–20.
[94]Watson MA,Stewart RK,Smith GB,Massey TE,Bell DA.Human glutathione S-transferase P1 polymorphisms:relation-ship to lung tissue enzyme activity and population frequency distribution.Carcinogenesis 1998;19:275–80.
[95]Allan JM,Wild CP,Rollinson S,Willett EV,Moorman AV,Dovey GJ,et al.Polymorphism in glutathione S-transferase P1is associated with susceptibility to chemotherapy-induced leukemia.Proc Natl Acad Sci U S A 2001;98:11592–7.
[96]Hayes JD,Pulford DJ.The glutathione S-transferase supergene family:regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance.Crit Rev Biochem Mol Biol 1995;30:445–600.
[97]Saburi Y,Nakagawa M,Ono M,Sakai M,Muramatsu M,Kohno K,et al.Increased expression of glutathione S-transferase gene in cis-diamminedichloro-platinum(ii)-resistant variants of a Chinese hamster ovary cell line.Cancer Res 1989;49:7020–5.
[98]Watson MB,Lind MJ,Smith L,Drew PJ,Cawkwell L.Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model.Acta Oncol2007;46:651–8.
[99]Smith L,Welham KJ,Watson MB,Drew PJ,Lind MJ,Cawkwell L.The proteomic analysis of cisplatin resistance in breast cancer cells.Oncol Res 2007;16:497–506.
[100]Wheeler HE,Gamazon ER,Stark AL,O’Donnel PH,Gorsic LK,et al.Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations.Pharmacogenomics J 2013;13:35–43.
[101]Hayes JD,Strange RC.Glutathione S-transferase polymorphisms and their biological consequences.Pharmacology 2000;61:154–66.
[102]Lin HJ,Han CY,Bernstein DA,Hsiao W,Lin BK,Hardy S.Ethnic distribution of the glutathione transferase mu-1-1(GSTM1)null genotype in 1473 individuals and application to bladder-cancer susceptibility.Carcinogenesis 1994;15:1077–81.
[103]Horgan AM,Yang B,Azad AK,Amir E,John T,Cescon DW,et al.Pharmacogenetic and germline prognostic markers of lung cancer.J Thorac Oncol 2011;6:296–304.
[104]Sweeney C,Nazar-Stewart V,Stapleton PL,Eaton DL,Vaughan TL.Glutathione S-transferase M1,T1,and P1 polymorphisms and survival among lung cancer patients.Cancer Epidemiol Biomarkers Prev 2003;12:527–33.
[105]Gonlugur U,Pinarbasi H,Gonlugur TE,Silig Y.The association between polymorphisms in glutathione S-transferase(GSTM1and GSTT1)and lung cancer outcome.Cancer Invest2006;24:497–501.
[2]American Cancer Society.Cancer facts and figures2014.Atlanta:American Cancer Society;2014.
[3]Yin JY,Huang Q,Zhao YC,Zhou HH,Liu ZQ.Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer(NSCLC)patients.PLo S One2012;7:e38150.
[4]National Cancer Institute.Non-small cell lung cancer treatment.
[5]Siegel R,Ma J,Zou Z,Jemal A.Cancer statistics,2014.CA Cancer J Clin 2014;64:9–29.
[6]Kuo MT,Chen HH,Song IS,Savaraj N,Ishikawa T.The roles of copper transporters in cisplatin resistance.Cancer Metastasis Rev 2007;26:71–83.
[7]van der Straaten T,Mullenders L,Guchelaar HJ.Pharmacogenetics of cancer and DNA repair enzymes.In:Vengrova S,editor.DNA repair and human health[internet].Richardson:Intech;2011.p.597–612.
[8]Rabik CA,Dolan ME.Molecular mechanisms of resistance and toxicity associated with platinating agents.Cancer Treat Rev2007;33:9–23.
[9]Huang JC,Zamble DB,Reardon JT,Lippard SJ,Sancar A.HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.Proc Natl Acad Sci U S A 1994;91:10394–8.
[10]Fichtinger-Schepman AM,van der Veer JL,den Hartog JH,Lohman PH,Reedijk J.Adducts of the antitumor drug cisdiamminedichloroplatinum(ii)with DNA–formation,identification,and quantitation.Biochemistry 1985;24:707–13.
[11]Zamble DB,Mu D,Reardon JT,Sancar A,Lippard SJ.Repair of cisplatin-DNA adducts by the mammalian excision nuclease.Biochemistry 1996;35:10004–13.
[12]Kartalou M,Essigmann JM.Mechanisms of resistance to cisplatin.Mutat Res Fundam Mol Mech Mutagen2001;478:23–43.
[13]Rosell R,Lord RV,Taron M,Reguart N.DNA repair and cisplatin resistance in non-small-cell lung cancer.Lung Cancer2002;38:217–27.
[14]Furuta T,Ueda T,Aune G,Sarasin A,Kraemer KH,Pommier Y.Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.Cancer Res2002;62:4899–902.
[15]Rosell R,Taron M,Barnadas A,Scagliotti G,Sarries C,Roig B.Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.Cancer Control2003;10:297–305.
[16]De Silva IU,Mc Hugh PJ,Clingen PH,Hartley JA.Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.Nucleic Acids Res 2002;30:3848–56.
[17]Dabholkar M,Vionnet J,Bostickbruton F,Yu JJ,Reed E.Messenger-RNA levels of XPAC and ERCC1 in ovarian-cancer tissue correlate with response to platinum-based chemotherapy.J Clin Invest 1994;94:703–8.
[18]Takenaka T,Yoshino I,Kouso H,Ohba T,Yohena T,Osoegawa A,et al.Combined evaluation of Rad51 and ERCC1expressions for sensitivity to platinum agents in non-small cell lung cancer.Int J Cancer 2007;121:895–900.
[19]Wang L,Wei J,Qian X,Yin H,Zhao Y,Yu L,et al.ERCC1and BRCA1 m RNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.BMC Cancer 2008;8:97.
[20]Lord RV,Brabender J,Gandara D,Alberola V,Camps C,Domine M,et al.Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.Clin Cancer Res 2002;8:2286–91.
[21]Cobo M,Isla D,Massuti B,Montes A,Sanchez JM,Provencio M,et al.Customizing cisplatin based on quantitative excision repair cross-complementing 1 m RNA expression:a phase III trial in non-small-cell lung cancer.J Clin Oncol 2007;25:2747–54.
[22]Olaussen KA,Dunant A,Fouret P,Brambilla E,Andre F,Haddad V,et al.DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.N Engl J Med 2006;355:983–91.
[23]Fan W,Zhang HL,Wu XM.Enhancement effect of nucleotide excision repair gene xeroderma pigmentosum group A antisense RNA on sensitivity of human lung adenocarcinoma cell line A549 to cisplatin.Chin J Cancer 2005;24:403–7.
[24]Zhang Q,Wu JX,Wei YP,Hao JQ,Huang SY,Dong L.Effect of XPA expression on the chemotherapy sensitivity of A549/DDP cells.Chin J Cell Mol Immunol 2012;28:1182–4.
[25]Liu Y,Bernauer AM,Yingling CM,Belinsky SA.HIF1 alpha regulated expression of XPA contributes to cisplatin resistance in lung cancer.Carcinogenesis 2012;33:1187–92.
[26]Chen HH,Yan JJ,Chen WC,Kuo MT,Lai YH,Lai WW,et al.Predictive and prognostic value of human copper transporter 1(h Ctr1)in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.Lung Cancer 2012;75:228–34.
[27]Song IS,Savaraj N,Siddik ZH,Liu PM,Wei YJ,Wu CJ,et al.Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.Mol Cancer Ther 2004;3:1543–9.
[28]Lin XJ,Okuda T,Holzer A,Howell SB.The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae.Mol Pharmacol 2002;62:1154–9.
[29]Ishida S,Lee J,Thiele DJ,Herskowitz I.Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals.Proc Natl Acad of Sci U S A2002;99:14298–302.
[30]Li ZH,Qiu MZ,Zeng ZL,Luo HY,Wu WJ,Wang F,et al.Copper-transporting P-type adenosine triphosphatase(ATP7A)is associated with platinum-resistance in non-small cell lung cancer(NSCLC).J Transl Med 2012;10:21.
[31]Song L,Li Y,Li W,Wu S,Li Z.Mi R-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper transporting P-type adenosine triphosphatase A(ATP7A).J Cell Biochem 2014;115:1234–42.
[32]Nakayama K,Kanzaki A,Terada K,Mutoh M,Ogawa K,Sugiyama T,et al.Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.Clin Cancer Res 2004;10:2804–11.
[33]Konkimalla VB,Kaina B,Efferth T.Role of transporter genes in cisplatin resistance.In Vivo 2008;22:279–83.
[34]Inoue Y,Matsumoto H,Yamada S,Kawai K,Suemizu H,Gika M,et al.ATP7B expression is associated with in vitro sensitivity to cisplatin in non-small cell lung cancer.Oncol Lett2010;1:279–82.
[35]Nakagawa T,Inoue Y,Kodama H,Yamazaki H,Kawai K,Suemizu H,et al.Expression of copper-transporting P-type adenosine triphosphatase(ATP7B)correlates with cisplatin resistance in human non-small cell lung cancer xenografts.Oncol Rep 2008;20:265–70.
[36]Nakagawa K,Yokota J,Wada M,Sasaki Y,Fujiwara Y,Sakai M,et al.Levels of glutathione S transferase pi m RNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin.Jpn J Cancer Res 1988;79:301–4.
[37]Arai T,Yasuda Y,Takaya T,Yoshimi N,Ito H,Fujiwara H.Correlation between the immunohistochemical and m RNA expression of glutathione S-transferase-pi and cisplatin plus etoposide chemotherapy response in patients with untreated primary non-small cell lung cancer.Int J Oncol 1997;11:127–31.
[38]Arai T,Yasuda Y,Takaya T,Hayakawa K,Toshima S,Shibuya C,et al.Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small-cell lung cancer.Cancer Detect Prev 2000;24:252–7.
[39]Hida T,Ariyoshi Y,Kuwabara M,Sugiura T,Takahashi T,Hosoda K,et al.Glutathione S-transferase pi levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity.Jpn J Clin Oncol 1993;23:14–9.
[40]Hirano T,Kato H,Maeda M,Gong YB,Shou YN,Nakamura M,et al.Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker.Int J Cancer 2005;117:460–8.
[41]Allen TC,Granville LA,Cagle PT,Haque A,Zander DS,Barrios R.Expression of glutathione S-transferase pi and glutathione synthase correlates with survival in early stage nonsmall cell carcinomas of the lung.Hum Pathol 2007;38:220–7.
[42]Rosell R,Scagliotti G,Danenberg KD,Lord RV,Bepler G,Novello S,et al.Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.Oncogene 2003;22:3548–53.
[43]Townsend AJ,Tu CP,Cowan KH.Expression of human mu or alpha class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells:effect on cellular sensitivity to cytotoxic agents.Mol Pharmacol 1992;41:230–6.
[44]Waxman DJ,Sundseth SS,Srivastava PK,Lapenson DP.Genespecific oligonucleotide probes for alpha,mu,pi,and microsomal rat glutathione S-transferases:analysis of liver transferase expression and its modulation by hepatic enzyme inducers and platinum anticancer drugs.Cancer Res 1992;52:5797–802.
[45]Wang CH,Wu HT,Cheng HM,Yen TJ,Lu IH,Chang HC,et al.Inhibition of glutathione S-transferase M1 by new gabosine analogues is essential for overcoming cisplatin resistance in lung cancer cells.J Med Chem 2011;54:8574–81.
[46]Wachters FM,Wong LS,Timens W,Kampinga HH,Groen HJ.ERCC1,h Rad51,and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.Lung Cancer 2005;50:211–9.
[47]Booton R,Ward T,Ashcroft L,Morris J,Heighway J,Thatcher N.ERCC1 m RNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.J Thorac Oncol2007;2:902–6.
[48]Glaysher S,Yiannakis D,Gabriel FG,Johnson P,Polak ME,Knight LA,et al.Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer(NSCLC).BMC Cancer 2009;9:1–17.
[49]Friboulet L,Olaussen KA,Pignon JP,Shepard FA,Tsao MS,Graziano S,et al.ERCC1 isoform expression and DNA repair in non-small cell lung cancer.N Engl J Med 2013;368:1101–10.
[50]Schneider JG,Farhadfar N,Sivapiragasam A,Geller M,Islam S,Selbs E.Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.Oncologist 2014;19:459–65.
[51]Stewart DJ.Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.Crit Rev Oncol Hematol 2010;75:173–234.
[52]Wei SZ,Zhan P,Shi MQ,Shi Y,Qian Q,Yu LK,et al.Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinumbased chemotherapy:a systematic review and meta-analysis.Med Oncol 2011;28:315–21.
[53]Wei HB,Hu J,Shang LH,Zhang YY,Lu FF,Wei M,et al.A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced nonsmall cell lung cancer.Chin Med J(Engl)2012;125:2902–7.
[54]Yu D,Shi J,Sun T,Du X,Liu L,Zhang X,et al.Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.Tumor Biol 2012;33:877–84.
[55]Qin Q,Zhang C,Yang X,Zhu H,Yang B,Cai J,et al.Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients:a meta-analysis of 24 studies.PLo S One 2013;8:e79864.
[56]Xu X,Duan L,Zhou B,Ma R,Zhou H,Liu Z.Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.Clin Exp Pharmacol Physiol 2012;39:786–92.
[57]Wu X,Lu C,Ye Y,Chang J,Yang H,Lin J,et al.Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy.Pharmacogenet Genomics 2008;18:955–65.
[58]Sun N,Sun X,Chen B,Cheng H,Feng J,Cheng L,et al.MRP2and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.Cancer Chemother Pharmacol 2010;65:437–46.
[59]Zhou F,Yu Z,Jiang T,Lv H,Yao R,Liang J.Genetic polymorphisms of GSTP1 and XRCC1:prediction of clinical outcome of platinum-based chemotherapy in advanced nonsmall cell lung cancer(NSCLC)patients.Swiss Med Wkly2011;141:w13275.
[60]Booton R,Ward T,Heighway J,Ashcroft L,Morris J,Thatcher N.Glutathione S-transferase P1 isoenzyme polymorphisms,platinum-based chemotherapy,and non-small cell lung cancer.J Thorac Oncol 2006;1:679–83.
[61]Lu C,Spitz MR,Zhao H,Dong Q,Truong M,Chang JY,et al.Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma.Cancer 2006;106:441–7.
[62]Yang Y,Xian L.The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer(NSCLC)patients:a meta-analysis.Tumor Biol2014;35:6791–9.
[63]Moyer AM,Sun Z,Batzler AJ,Li L,Schaid DJ,Yang P,et al.Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy.Cancer Epidemiol Biomarkers Prev 2010;19:811–21.
[64]Wu XM,Fan W,Xu SW,Zhou YK.Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosum group A antisense RNA in human lung adenocarcinoma cells.Clin Cancer Res2003;9:5874–9.
[65]Rosenberg E,Taher MM,Kuemmerle NB,Farnsworth J,Valerie K.A truncated human xeroderma pigmentosum complementation group a protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin.Cancer Res 2001;61:764–70.
[66]Gately DP,Howell SB.Cellular accumulation of the anticancer agent cisplatin:a review.Br J Cancer 1993;67:1171–6.
[67]Kim ES,Lee JJ,He G,Chow CW,Fujimoto J,Kalhor N,et al.Tissue platinum concentration and tumor response in non-smallcell lung cancer.J Clin Oncol 2012;30:3345–52.
[68]Zhou B,Gitschier J.HCTR1:a human gene for copper uptake identified by complementation in yeast.Proc Natl Acad Sci U S A 1997;94:7481–6.
[69]Safaei R,Howell SB.Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.Crit Rev Oncol Hematol 2005;53:13–23.
[70]Holzer AK,Manorek GH,Howell SB.Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin,carboplatin,and oxaliplatin.Mol Pharmacol2006;70:1390–4.
[71]Zisowsky J,Koegel S,Leyers S,Devarakonda K,Kassack MU,Osmak M,et al.Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.Biochem Pharmacol2007;73:298–307.
[72]Larson CA,Blair BG,Safaei R,Howell SB.The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.Mol Pharmacol 2009;75:324–30.
[73]Larson CA,Adams PL,Jandial DD,Blair BG,Safaei R,Howell SB.The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin.Biochem Pharmacol 2010;80:448–54.
[74]Kalayda GV,Wagner CH,Jaehde U.Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.J Inorg Biochem 2012;116:1–10.
[75]Ishida S,Mc Cormick F,Smith-Mc Cune K,Hanahan D.Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.Cancer Cell 2010;17:574–83.
[76]Fu S,Naing A,Fu C,Kuo MT,Kurzrock R.Overcoming platinum resistance through the use of a copper-lowering agent.Mol Cancer Ther 2012;11:1221–5.
[77]Ivy KD,Kaplan JH.A re-evaluation of the role of h CTR1,the human high-affinity copper transporter,in platinum-drug entry into human cells.Mol Pharmacol 2013;83:1237–46.
[78]Hall MD,Okabe M,Shen DW,Liang XJ,Gottesman MM.The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.Annu Rev Pharmacol Toxicol2008;48:495–535.
[79]Wee NK,Weinstein DC,Fraser ST,Assinder SJ.The mammalian copper transporters CTR1 and CTR2 and their roles in development and disease.Int J Biochem Cell Biol 2013;45:960–3.
[80]Blair BG,Larson CA,Safaei R,Howell SB.Copper transporter2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.Clin Cancer Res 2009;15:4312–21.
[81]Huang CP,Fofana M,Chan J,Chang CJ,Howell SB.Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.Metallomics 2014;6:654–61.
[82]Ohrvik H,Thiele DJ.The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy.J Trace Elem Med Biol 2014.http://dx.doi.org/10.1016/j.jtemb.2014.03.006.
[83]Vulpe C,Levinson B,Whitney S,Packman S,Gitschier J.Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase.Nat Genet1993;3:7–13.
[84]Bull PC,Thomas GR,Rommens JM,Forbes JR,Cox DW.The Wilson disease gene is a putative copper transporting p-type ATPase similar to the Menkes gene.Nat Genet 1993;5:327–37.
[85]Samimi G,Varki NM,Wilczynski S,Safaei R,Alberts DS,Howell SB.Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.Clin Cancer Res2003;9:5853–9.
[86]Samimi G,Safaei R,Katano K,Holzer AK,Rochdi M,Tomioka M,et al.Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin,carboplatin,and oxaliplatin in ovarian cancer cells.Clin Cancer Res2004;10:4661–9.
[87]Komatsu M,Sumizawa T,Mutoh M,Chen ZS,Terada K,Furukawa T,et al.Copper-transporting P-type adenosine triphosphatase(ATP7B)is associated with cisplatin resistance.Cancer Res 2000;60:1312–6.
[88]Hildebrandt MA,Gu J,Wu X.Pharmacogenomics of platinumbased chemotherapy in NSCLC.Expert Opin Drug Metab Toxicol 2009;5:745–55.
[89]Fukushima-Uesaka H,Saito Y,Maekawa K,Kurose K,Sugiyama E,Katori N,et al.Genetic polymorphisms of copperand platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients.Drug Metab Pharmacokinet2009;24:565–74.
[90]Anttila S,Hirvonen A,Vainio H,Husgafvel-Pursiainen K,Hayes JD,Ketterer B.Immunohistochemical localization of glutathione S-transferases in human lung.Cancer Res1993;53:5643–8.
[91]Terrier P,Townsend AJ,Coindre JM,Triche TJ,Cowan KH.An immunohistochemical study of pi-class glutathione S-transferase expression in normal human tissue.Am J Pathol1990;137:845–53.
[92]Peklak-Scott C,Smitherman PK,Townsend AJ,Morrow CS.Role of glutathione S-transferase P1–1 in the cellular detoxification of cisplatin.Mol Cancer Ther 2008;7:3247–55.
[93]Tew KD.Glutathione-associated enzymes in anticancer drugresistance.Cancer Res 1994;54:4313–20.
[94]Watson MA,Stewart RK,Smith GB,Massey TE,Bell DA.Human glutathione S-transferase P1 polymorphisms:relation-ship to lung tissue enzyme activity and population frequency distribution.Carcinogenesis 1998;19:275–80.
[95]Allan JM,Wild CP,Rollinson S,Willett EV,Moorman AV,Dovey GJ,et al.Polymorphism in glutathione S-transferase P1is associated with susceptibility to chemotherapy-induced leukemia.Proc Natl Acad Sci U S A 2001;98:11592–7.
[96]Hayes JD,Pulford DJ.The glutathione S-transferase supergene family:regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance.Crit Rev Biochem Mol Biol 1995;30:445–600.
[97]Saburi Y,Nakagawa M,Ono M,Sakai M,Muramatsu M,Kohno K,et al.Increased expression of glutathione S-transferase gene in cis-diamminedichloro-platinum(ii)-resistant variants of a Chinese hamster ovary cell line.Cancer Res 1989;49:7020–5.
[98]Watson MB,Lind MJ,Smith L,Drew PJ,Cawkwell L.Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model.Acta Oncol2007;46:651–8.
[99]Smith L,Welham KJ,Watson MB,Drew PJ,Lind MJ,Cawkwell L.The proteomic analysis of cisplatin resistance in breast cancer cells.Oncol Res 2007;16:497–506.
[100]Wheeler HE,Gamazon ER,Stark AL,O’Donnel PH,Gorsic LK,et al.Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations.Pharmacogenomics J 2013;13:35–43.
[101]Hayes JD,Strange RC.Glutathione S-transferase polymorphisms and their biological consequences.Pharmacology 2000;61:154–66.
[102]Lin HJ,Han CY,Bernstein DA,Hsiao W,Lin BK,Hardy S.Ethnic distribution of the glutathione transferase mu-1-1(GSTM1)null genotype in 1473 individuals and application to bladder-cancer susceptibility.Carcinogenesis 1994;15:1077–81.
[103]Horgan AM,Yang B,Azad AK,Amir E,John T,Cescon DW,et al.Pharmacogenetic and germline prognostic markers of lung cancer.J Thorac Oncol 2011;6:296–304.
[104]Sweeney C,Nazar-Stewart V,Stapleton PL,Eaton DL,Vaughan TL.Glutathione S-transferase M1,T1,and P1 polymorphisms and survival among lung cancer patients.Cancer Epidemiol Biomarkers Prev 2003;12:527–33.
[105]Gonlugur U,Pinarbasi H,Gonlugur TE,Silig Y.The association between polymorphisms in glutathione S-transferase(GSTM1and GSTT1)and lung cancer outcome.Cancer Invest2006;24:497–501.